Cover image of the article: Synthesis and Primary Cytotoxic Screening of Some 3- Sulfonamide Substituted Benzamido-benzimidazolones

Image Credit:Iran J Pharm Res

Synthesis and Primary Cytotoxic Screening of Some 3- Sulfonamide Substituted Benzamido-benzimidazolones

Authors

Ghadam Ali Khodarahmi1,*, Pei-Yu Chen2, 3, Gholam-Hosein Hakimelahi1, 4, Ji-Wang Chern2
1Department of Medicinal Chemistry, Faculty of Pharmacy, Isfahan Univercity of Medical Sciences , Isfahan, Iran
2School of Pharmacy, National Taiwan University, Taipei, Taiwan
3Maine Medical Center Research Institute, Scarborough, ME, USA
4Institutes of Chemistry and Biomedical Sciences, Academia Sinica, Taipei, Taiwan
*Corresponding Author: Department of Medicinal Chemistry, Faculty of Pharmacy, Isfahan Univercity of Medical Sciences , Isfahan, Iran. Email:khodarahmi@pharm.mui.ac.ir

Iranian Journal of Pharmaceutical Research:Vol. 4, issue 1; 43-56
Published online:Nov 20, 2010
Article type:Research Article
Received:Jun 01, 2004
Accepted:Mar 01, 2005
How to Cite:Khodarahmi GA, Chen P, Hakimelahi G, Chern J. Synthesis and Primary Cytotoxic Screening of Some 3- Sulfonamide Substituted Benzamido-benzimidazolones. Iran J Pharm Res. 2022;4(1):e128226. doi: https://doi.org/10.22037/ijpr.2010.616

Abstract

Several cycline dependent kinase 2 (CDK2) inhibitors with different chemical structures have been introduced. The hinge region of CDK2 (residues 81–84) contains a set of hydrogen bond donor and acceptor sites some of which must be satisfied for potent inhibitor binding. The benzimidazolone skeleton may provide such interactions. Accordingly, 3-sulfonamide substituted benzamido-benzimidazolones 24-31 were prepared starting from benzoic acid to give the acyl chloride 1 which was reacted with different amines to afford the acids 2-9. The acids were changed to their corresponding acyl chlorides 10-17. Reaction of 10-17 with o-nitropheyl hydrazine gave the nitro derivatives 18-25 followed by reduction of the nitro groups to give 26-33 which were then reacted with ethyl chloroformate to give the target compounds 34-41. The 3-pyridyl derivative 47 was prepared starting with chlorosulfonyl benzoyl chloride to give the acid 43 which was changed to the corresponding acyl, nitro and amino derivatives 44, 45 and 46, respectively, followed by the final ring closure reaction to give 47. The dibenzimidazolinoe derivative 49 was also obtained from the reaction of isopropenyl-benzimidazolone 48 and 3-chloro sulfonyl benzoyl chloride. The target compounds were then tested against the cancer cell lines, Hepa G2, HT-29, CL1-5 and AGS. Results indicated that the target compounds did not show reasonable cell growth inhibition comparing to the positive and negative controls.

Highlights

Copyright

© 2022, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

20
Mar
2012
Synthesis, Molecular Docking and Cytotoxicity Evaluation of 2-(4-Substituted-Benzyl) Isoindoline-1, 3-Dione Derivatives as Anticancer Agents

Synthesis, Molecular Docking and Cytotoxicity Evaluation of 2-(4-Substituted-Benzyl) Isoindoline-1, 3-Dione Derivatives as Anticancer Agents

Alireza Aliabadi,
Alireza Foroumadi,
Maliheh Safavi,
Sussan Kabudanian Ardestani

Aliabadi A, Foroumadi A, Safavi M, Kabudanian Ardestani S. Synthesis, Molecular Docking and Cytotoxicity Evaluation of 2-(4-Substituted-Benzyl) Isoindoline-1, 3-Dione Derivatives as Anticancer Agents. J Rep Pharm Sci. 2012;1(1):e147800. doi:

30
Apr
2017
Synthesis and Anticancer Activity Assay of Novel Chalcone-Sulfonamide Derivatives

Synthesis and Anticancer Activity Assay of Novel Chalcone-Sulfonamide Derivatives

Ahmad Pesaran Seiied Bonakdar,
Farzane Vafaei,
Mahbobeh Farokhpour,
Mohammad Hossein Nasr Esfahani,
Ahmad Reza Massah

Pesaran Seiied Bonakdar A, Vafaei F, Farokhpour M, Nasr Esfahani MH, Massah AR. Synthesis and Anticancer Activity Assay of Novel Chalcone-Sulfonamide Derivatives. Iran J Pharm Res. 2017;16(2):e125028. doi: https://doi.org/10.22037/ijpr.2017.2036

31
Jul
2015
Design and Synthesis of New Benzimidazole and Pyrimidine Derivatives as α-glucosidase Inhibitor

Design and Synthesis of New Benzimidazole and Pyrimidine Derivatives as α-glucosidase Inhibitor

Akbar Mobinikhaledi,
Behvar Asghari,
Mahsa Jabbarpour

Mobinikhaledi A, Asghari B, Jabbarpour M. Design and Synthesis of New Benzimidazole and Pyrimidine Derivatives as α-glucosidase Inhibitor. Iran J Pharm Res. 2015;14(3):e125327. doi: https://doi.org/10.22037/ijpr.2015.1672

31
Jul
2016
Synthesis and Docking Analysis of New Heterocyclic System N1, N4-bis (2-chloroquinolin-3-yl) methylene) benzene-1, 4-diamine as Potential Human AKT1 Inhibitor

Synthesis and Docking Analysis of New Heterocyclic System N1, N4-bis (2-chloroquinolin-3-yl) methylene) benzene-1, 4-diamine as Potential Human AKT1 Inhibitor

Sohrab Ghanei,
Jalil Lari,
Hossein Eshghi,
Mohammad Saadatmandzadeh

Ghanei S, Lari J, Eshghi H, Saadatmandzadeh M. Synthesis and Docking Analysis of New Heterocyclic System N1, N4-bis (2-chloroquinolin-3-yl) methylene) benzene-1, 4-diamine as Potential Human AKT1 Inhibitor. Iran J Pharm Res. 2016;15(3):e125167. doi: https://doi.org/10.22037/ijpr.2016.1895

31
Jan
2016
Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents

Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents

Walaa S. El-serwy,
Neama A. Mohamed,
Emad M. M. Kassem,
Khaled Mahmoud,
M. M Mounier

El-serwy WS, A. Mohamed N, M. M. Kassem E, Mahmoud K, Mounier MM. Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents. Iran J Pharm Res. 2016;15(1):e125119. doi: https://doi.org/10.22037/ijpr.2016.1799

More by these authors

Ghadam Ali KhodarahmiPubMedScholar
Pei-Yu ChenPubMedScholar
Gholam-Hosein HakimelahiPubMedScholar
Ji-Wang ChernPubMedScholar
Share
Cited by
Metrics